/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that invents, develops, manufactures, and commercializes medicines aimed at treating serious diseases across multiple therapeutic areas. Valued at a market cap of $59.1 billion, the company is expected to announce its fiscal Q3 earnings for 2025 before the market opens on Tuesday, Oct. 28.
Before this event, analysts expect this healthcare company to report a profit of $7.80 per share, down 33.5% from $11.73 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $12.89 per share in the previous quarter outpaced the consensus estimates by a notable margin of 60.5%.
